OGD's Sporn moving to Abbott
This article was originally published in The Tan Sheet
Executive Summary
FDA Office of Generic Drugs Director Douglas Sporn is joining Abbott Labs as divisional VP, corporate regulatory affairs March 1. OGD Deputy Director Gary Buehler will serve as acting director. Sporn has been with CDER since 1990 and has led the generics division since 1996. In his 26 years at the agency, Sporn also has served as deputy director of the Office of Pharmaceutical Sciences and held positions in the commissioner's office and the Center for Devices & Radiological Health. Sporn is the second FDAer to move to Abbott in the last three months; former CBER Deputy Director Michael Beatrice joined the firm as VP-corporate regulatory and quality science in November. Sporn reports to Beatrice in his new post
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning